This article has Open Peer Review reports available.
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
© Arampatzis et al; licensee BioMed Central Ltd. 2011
Received: 30 March 2011
Accepted: 5 July 2011
Published: 5 July 2011
Although renal involvement in advanced haematological malignancies is common, glomerulonephritis associated with lymphoproliferative disorders is rare, and the related pathogenetic mechanisms are still poorly understood. We present a rare case of chronic lymphocytic leukaemia(CLL)-associated focal segmental glomerulosclerosis with nephrotic-range proteinuria.
A 53-year-old Caucasian man, previously healthy, with no history of hypertension, alcohol use or smoking presented with rapid weight gain, massive peripheral oedema, and hypertension. Laboratory findings included a white blood cell count of 49,800 cells/mm3 with an absolute lymphocyte count of 47,000 cells/mm3, serum albumin of 2.3 g/dL, urea 65 mg/dL, and creatinine 1.5 mg/dL. A 24-hour urine collection contained 7.1 g protein and significant haematuria. A peripheral blood smear showed mature lymphocytosis and smudge cells. Diagnostic imaging showed mild paraaortic lymphadenopathy with no renal abnormalities. Bone marrow aspiration and trephine biopsy showed diffuse and focal infiltration with B-CLL lymphocytes. Percutaneous renal biopsy revealed total sclerosis in 3/21(14%) of the glomeruli and focal and segmental solidification and sclerosis in 4/21 (19%) glomeruli. A regimen of fludarabine, cyclophosphamide and rituximab was successful in inducing remission of the CLL and clinical resolution of the nephritic-range proteinuria.
A multidisciplinary approach to monitor both the malignancy and the glomerular lesions is crucial for the optimal management of paraneoplastic glomerulonephritis. Although chemotherapy with fludarabine, cyclophosphamide and rituximab successfully treated CLL-associated nephrotic syndrome in our patient, further studies are required to confirm efficacy in this setting.
Keywordschronic lymphocytic leukemia focal segmental glomerulosclerosis nephrotic syndrome fludarabine cyclophosphamide rituximab
Although renal involvement in advanced haematological malignancies is common, glomerulonephritis associated with lymphoproliferative disorders is rare, and the related pathogenetic mechanisms are still poorly understood . Chronic lymphocytic leukemia (CLL) is more commonly associated with membranoproliferative glomerulonephritis and membranous nephropathy whereas minimal change disease is the most common paraneoplastic glomerulonephritis associated with Hodgkin lymphoma, followed by focal segmental glomerulosclerosis (FSGS) . We report on a patient with CLL who presented with NS-associated FSGS - a rare association.
After initial treatment with enoxaparin s.c., valsartan and a statin, the patient received six courses of intravenous fludarabine (25 mg/m2 d1-3), cyclophosphamide (350 mg/m2 d1) and rituximab (375 mg/m2 d1). Each cycle was given every four weeks under continuous prophylactic therapy with acyclovir and trimethoprim-sulfamethoxazole.
The patient showed a gradual response to therapy (Figure 1). One month after the fourth dose, he had complete resolution of oedema, the WBC count had decreased to 3,500/mm3 (ALC: 0.98/mm3), and urinary protein excretion had dropped to 0.7/g/day. Serum creatinine was normal at 1.0 g/dL, serum cholesterol had decreased to 195 mg/dL, and serum albumin had increased to 4.4 g/dL. Immunoglobulin and beta2 microglobulin values were normal. After completion of the 6 cycles of therapy, a CT scan of the thorax and abdomen was normal. Bone marrow aspiration and trephine biopsy showed normal haematopoietic cells without clonal B cells. The patient continued to receive rituximab (375 mg/m2 every 3 months) as maintenance therapy for the next 24 months. At the last follow up 28 months after diagnosis the patient remains in complete remission and the urinary protein excretion is below 200 mg/day under antihypertensive treatment.
Fludarabine, cyclophosphamide and rituximab (FCR) therapy is becoming the frontline treatment for CLL, especially in younger patients. These agents act synergistically and are associated with high complete remission rates and long durations of remission . Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by marked proteinuria, hypertension, and a high incidence of progression to renal failure . The pathogenesis of primary FSGS remains unclear but several observations support the hypothesis that there is a causative factor present in the circulation of some patients with FSGS . The recommendations for initial immunosuppressant treatment with prednisone or cyclosporine are largely based upon small clinical studies. Data on the use of cyclophosphamide and other cytotoxic drugs for steroid-dependent or steroid-resistant FSGS in adults are limited to a few retrospective observational studies.
The alkylating agent cyclophosphamide has been primary used in children with relapsing or steroid resistant FSGS. Rituximab is a chimeric CD20-reactive monoclonal antibody with established efficacy in B-cell lymphomas. Binding of the antibody to the CD20 antigen results in selective lysis of targeted B cells. Recently, several case reports demonstrated the successful use of rituximab in a variety of systemic diseases with renal involvement and also in steroid resistant FSGS [6, 7]. In several recurrent post-transplant FSGS cases, NS resolved after rituximab treatment [8, 9]. Fludarabine, a purine analogue with selective activity against both dividing and resting lymphocytes, results in a profound decrease in CD4 lymphocytes that may last for years. Low-dose fludarabine treatment has been used only in patients with membranous nephropathy .
Since FSGS is not an antibody-mediated disease, improvement of NS with the FCR regime may seem surprising. However, B cells play an important role as immunoregulatory cells through antigen processing and presentation, recruitment of auto-reactive T cells, interaction with antigen presenting cells, and secretion of cytokines. B cell depletion under FCR may affect T cell activation and downregulate the costimulation status .
The primary site of glomerular injury in FSGS is the podocyte. A variety of factors have been postulated to cause injury to glomerular cells, including circulating cytokines such as permeability altering factor, angiotensin II, macrophage infiltration and other mediators of inflammation [12, 13]. Injury to the podocytes by a circulating toxin is further supported by the rapidity and relatively high incidence of disease recurrence in some patients after renal transplantation. Simultaneous presentation and long term remission of CLL and FSGS in our case is consistent with the interpretation that chemotherapy prevented the synthesis of a nephrotoxic circulating lymphokine secreted by malignant cells. A potential paraneoplastic link between malignancies and glomerulonephropathies is difficult to demonstrate, but is supported in our patient by the parallel improvement and longterm resolution of the two conditions under treatment.
A multidisciplinary approach to monitor both the malignancy and the glomerular lesions is crucial for the optimal management of paraneoplastic glomerulonephritis . Although chemotherapy with FRC successfully treated CLL-associated nephrotic syndrome in our patient, further studies are required to confirm efficacy in this setting.
Written consent was obtained from the patient for the publication of the case report. We thank Alistair Reeves for language editing.
- Da'as N, Polliack A, Cohen Y, Amir G, Darmon D, Kleinman Y, Goldfarb AW, Ben-Yehuda D: Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemial a retrospective study in 700 patients. Eur J Haematol. 2001, 67 (3): 158-164. 10.1034/j.1600-0609.2001.5790493.x.View ArticlePubMedGoogle Scholar
- Lien YH, Lai LW: Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011, 7 (2): 85-95. 10.1038/nrneph.2010.171.View ArticlePubMedGoogle Scholar
- Montserrat E: Further progress in CLL therapy. Blood. 2008, 112 (4): 924-925. 10.1182/blood-2008-05-155721.View ArticlePubMedGoogle Scholar
- Matalon A, Valeri A, Appel GB: Treatment of focal segmental glomerulosclerosis. Semin Nephrol. 2000, 20 (3): 309-317.PubMedGoogle Scholar
- Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ: Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol. 2003, 14 (2): 448-453. 10.1097/01.ASN.0000046960.57614.17.View ArticlePubMedGoogle Scholar
- Korbet SM, Schwartz MM, Lewis EJ: Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis. 1994, 23 (6): 773-783.View ArticlePubMedGoogle Scholar
- Salama AD, Pusey CD: Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol. 2006, 2 (4): 221-230. 10.1038/ncpneph0133.View ArticlePubMedGoogle Scholar
- Meyer TN, Thaiss F, Stahl RA: Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int. 2007, 20 (12): 1066-1071. 10.1111/j.1432-2277.2007.00562.x.View ArticlePubMedGoogle Scholar
- Pescovitz MD, Book BK, Sidner RA: Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006, 354 (18): 1961-1963. 10.1056/NEJMc055495.View ArticlePubMedGoogle Scholar
- Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y, Pucino F, Balow JE, Austin HA: A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol. 1999, 52 (2): 67-75.PubMedGoogle Scholar
- Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005, 52 (2): 501-513. 10.1002/art.20858.View ArticlePubMedGoogle Scholar
- Peters I, Tossidou I, Achenbach J, Woroniecki R, Mengel M, Park JK, Paschy M, de Groot K, Haller H, Schiffer M: IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol. 2006, 17 (6): 1644-1656. 10.1681/ASN.2005111209.View ArticlePubMedGoogle Scholar
- Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 2004, 65 (1): 30-39. 10.1111/j.1523-1755.2004.00362.x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/12/33/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.